Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
NAMPTi
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "NAMPTi" in MCE Product Catalog:
2
Nampt-IN-1 (LSN3154567) is a potent and selective NAMPT inhibitor. Nampt-IN-1 inhibits purified NAMPT with an IC50 of 3.1 nM.
Nampt-IN-10 TFA (compound 4) is a Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-10 TFA shows cellular potency to A2780 and CORL23 cells lines with IC50s of 5 and 19 nM, respectively. Nampt-IN-10 TFA can be used as a novel non-antimitotic payload for ADCs .
Cat. No.: HY-402237
CAS No.: 2222981-61-3
Target:
Research Areas:
Nampt-IN-15 (Example 3) is an Nampt inhibitor. Nampt-IN-15 shows cytotoxicity against BxPC-3, HepG2, L540cy and MOLM-13, with IC50s of 38.5 nM, 8 nM, 8.5 nM, 7 nM respectively .
Nampt-IN-3 (Compound 35) simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT) and HDAC with IC50s of 31 nM and 55 nM, respectively. Nampt-IN-3 effectively induces cell apoptosis and autophagy and ultimately leads to cell death .
Cat. No.: HY-147193A
Nampt-IN-10 trihydrochloride (compound 4) is a Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-10 trihydrochloride shows cellular potency to A2780 and CORL23 cell lines with IC50 values of 5 and 19 nM, respectively. Nampt-IN-10 trihydrochloride can be used as a novel non-antimitotic payload for antibody-drug conjugate (ADC) .
Cat. No.: HY-164759
CAS No.: 2592504-89-5
Target:
Research Areas:
Nampt-IN-13 is a NAMPT inhibitor that serves as a payload for the synthesis of ADCs. Nampt-IN-13 is applicable to cancer-related research .
Cat. No.: HY-W1117786
CAS No.: 2241015-68-7
Target:
Research Areas:
Nampt-IN-10 (Compound 4) is an efficient inhibitor of nicotinamide phosphoribosyltransferase (NAMPT). Nampt-IN-10 exhibits nanomolar-level inhibitory activity against cell lines such as MDA-MB453, NCI-N87, and NCI-H526. Nampt-IN-10 can be used as an ADC payload, and the ADC constructed with it as the core demonstrates significant anti-tumor activity .
Target:
Research Areas:
Nampt-IN-5 is a potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-5 also inhibits CYP3A4 activity and has cellular IC50s of 0.7 nM and 3.9 nM against A2780 and COR-L23, respectively .
Cat. No.: HY-147838
CAS No.: 2180973-35-5
Nampt-IN-9 (Compound 8) is a potent NAMPT inhibitor with anticancer activities. Nampt-IN-9 can be used for pancreatic ductal adenocarcinoma research .
Cat. No.: HY-176237
CAS No.: 3077970-44-3
Nampt-IN-16 (Compound 9a) is an orally active NAMPT inhibitor with an IC50 of 0.15 μM. Nampt-IN-16 can reduce intracellular NAD + and ATP levels. Nampt-IN-16 can inhibit the proliferation, migration, and invasion, induce cell cycle arrest and apoptosis, and alter cellular metabolism of gastric cancer cells. Nampt-IN-16 can be used in the research of tumors such as gastric cancer .
Cat. No.: HY-148572
CAS No.: 2247884-06-4
Research Areas:
NAMPT/IDO1-IN-1 is an orally active dual inhibitor of NAMPT and IDO1 with IC50s of 57.7 nM and 233 nM, respectively. NAMPT/IDO1-IN-1 blocks NAD+ biosynthesis, inhibits proliferation and migration of Paclitaxel (HY-B0015)- and FK866 (HY-50876)-resistant NSCLC cell lines (A549/R cells). NAMPT/IDO1-IN-1 has shown antitumor effects in mice and enhanced A549/R cell sensitivity to paclitaxel .
Cat. No.: HY-147756
CAS No.: 1223378-42-4
Nampt-IN-7 (compound GF8) is a potent NAMPT inhibitor, with an IC50 of 7.31 μM. Nampt-IN-7 also displays cytotoxic activity against human HepG2 hepatocellular carcinoma cell line with an IC50 of 24.28 μM .
Cat. No.: HY-147795
CAS No.: 2453183-75-8
Research Areas:
Nampt-IN-8 (Compound 10d) is an NAMPT inhibitor with an IC50 of 0.183 μM. Nampt-IN-8 is also a relatively good NQO1 substrate. Nampt-IN-8 induces cell apoptosis and ROS .
Cat. No.: HY-184467
CAS No.: 1362150-16-0
Nampt-IN-20 is a nicotinamide phosphoribosyltransferase (Nampt) inhibitor with a IC50 of 9.0 nM. Nampt-IN-20 binds to the active site of Nampt, occupies the NAM-binding region and disrupts NAD biosynthesis. Nampt-IN-20 exerts antiproliferative effects in A2780 ovarian cancer cells. Nampt-IN-20 can be used for the research of ovarian cancer .
Cat. No.: HY-181578
CAS No.: 3077970-78-3
Nampt-IN-17 is an selective orally active NAMPT inhibitor with a human NAMPT IC50 of 17 nM and Ki of 25.9 nM. Nampt-IN-17 depletes intracellular NAD + and ATP, disrupts mitochondrial membrane potential, suppresses cell proliferation, self-renewal, invasion, and migration, induces cell-cycle arrest and apoptosis. Nampt-IN-17 exhibits selective activity against NAPRT-deficient gastric cancer cells. Nampt-IN-17 can be used for the research of NAPRT-deficient gastric cancer .
Cat. No.: HY-181863
Target:
Research Areas:
Nampt-IN-18 (Compound Q24) is an orally active NAMPT inhibitor with an IC50 of 8.0 nM against hNAMPT. Nampt-IN-18 inhibits NAMPT enzymatic activity. Nampt-IN-18 inhibits DNA synthesis and induces Apoptosis. Nampt-IN-18 exhibits anticancer activity against gastric cancer and colorectal cancer. Nampt-IN-18 can be used for the research of gastrointestinal cancers .
Cat. No.: HY-182567
CAS No.: 2109805-79-8
Nampt-IN-19 is an orally active and non-substrate nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with a human Ki of 5.6 nM. Nampt-IN-19 blocks NAD + biosynthesis from Nicotinamide (HY-B0150). Nampt-IN-19 acts as an antiproliferative agent in cancer cells. Nampt-IN-19 has preclinical pharmacokinetic properties supporting oral antitumor activity in mouse xenograft models. Nampt-IN-19 can be used for the research of colorectal cancer .
Cat. No.: HY-187006
CAS No.: 1110983-52-2
Research Areas:
Nampt-IN-21 is a NAMPT inhibitor. Nampt-IN-21 serves as a Ligand for Target Protein for PROTAC for the synthesis of PROTAC NAMPT degraders, such as PROTAC NAMPT Degrader-30 (HY-152154). Nampt-IN-21 is applicable to the research of ovarian cancer .
Cat. No.: HY-187336
CAS No.: 3087291-80-0
Nampt-IN-22 is a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-22 blocks the NAD + salvage synthesis pathway by inhibiting nicotinamide phosphoribosyltransferase (NAMPT). Its tertiary alcohol forms hydrogen bonds with His191 of NAMPT and enhances lysosomal stability via intramolecular hydrogen bonds. As an ADC payload, Nampt-IN-22 exhibits low nanomolar cytotoxicity against tumor cells after conjugation to an anti-CD30 antibody, prolongs survival in a disseminated L540 Hodgkin lymphoma mouse model, and suppresses subcutaneous tumor growth. Nampt-IN-22 can be used in studies related to Hodgkin lymphoma .
Cat. No.: HY-108701R
CAS No.: 2121591-52-2
Nampt-IN-3 (Standard) is the analytical standard of Nampt-IN-3 (HY-108701). This product is intended for research and analytical applications. Nampt-IN-3 (Compound 35) simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT) and HDAC with IC50s of 31 nM and 55 nM, respectively. Nampt-IN-3 effectively induces cell apoptosis and autophagy and ultimately leads to cell death .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
